Retrospective database analysis focused on Famotidine but also showing results for HCQ users, with unadjusted mortality RR 0.85, p
<0.001 (13.6% vs. 16.1%).
Shoaibi et al., 9/24/2020, retrospective, database analysis, USA, North America, preprint, 5 authors.
risk of death, 15.4% lower, RR 0.85, p < 0.001, treatment 686 of 5047 (13.6%), control 3923 of 24404 (16.1%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.